Castle Biosciences (NASDAQ:CSTL) Insider Sells $526,582.12 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 20,863 shares of Castle Biosciences stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $25.24, for a total transaction of $526,582.12. Following the completion of the sale, the insider directly owned 86,825 shares of the company’s stock, valued at approximately $2,191,463. The trade was a 19.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Castle Biosciences Stock Performance

Shares of CSTL stock opened at $25.61 on Thursday. The company has a current ratio of 5.26, a quick ratio of 5.11 and a debt-to-equity ratio of 0.02. The firm has a fifty day simple moving average of $33.79 and a two-hundred day simple moving average of $31.74. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The firm has a market capitalization of $761.39 million, a PE ratio of -30.13 and a beta of 1.09.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15. The firm had revenue of $81.88 million for the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. Analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on CSTL. Lake Street Capital lifted their price target on Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, January 12th. BTIG Research raised their target price on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Morgan Stanley raised Castle Biosciences to a “buy” rating in a research report on Monday, March 2nd. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, March 2nd. Finally, KeyCorp reissued an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a research report on Thursday, January 29th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $47.57.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Castle Biosciences by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after buying an additional 27,511 shares in the last quarter. RTW Investments LP bought a new position in shares of Castle Biosciences in the fourth quarter valued at approximately $82,283,000. Principal Financial Group Inc. increased its position in shares of Castle Biosciences by 0.7% during the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock valued at $70,317,000 after acquiring an additional 13,289 shares during the last quarter. Portolan Capital Management LLC increased its position in shares of Castle Biosciences by 1.7% during the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock valued at $34,499,000 after acquiring an additional 25,539 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Castle Biosciences by 7.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock worth $33,564,000 after acquiring an additional 96,084 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.